AstraZeneca

Open: 68.28 Close: 68.94 Change: 0.66

What an AI can tell you about AstraZeneca Stock before investing.

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, cancer, evaluate, advance, rise, AstraZenecas, Bodes, and the most common words in the summary are: astrazeneca, news, subscribe, see, cancer, drug, company, . One of the sentences in the summary was: Jefferies upgraded AstraZenecas stock from hold to buy after positive results from a late-stage …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Jefferies upgraded AstraZenecas stock from hold to buy after positive results from a late-stage study evaluating its antibody-drug conjugate, Dato-DXd. Elmarie Bodes claims AstraZecas refused to pay her more than $125,000 in bonuses.

Today's News

AstraZeneca and Daiichi Sankyo have two additional Phase III trials evaluating datopotamab deruxtecan in breast cancer. Astra has the vision to redefine cancer care and, one day, eliminate cancer. AstraZeneca provides this link as a service to website visitors. AstraZecas is not responsible for the privacy policy. The AstraZeneca PLC ADR AZN, +1.64% advanced 1.64%. The NASDAQ Composite Index COMP, +0.45% rising 0.45%. The Dow Jones Industrial Average DJIA rose 0.13%. Jefferies upgraded AstraZenecas stock from hold to buy after positive results from a late-stage study evaluating its antibody-drug conjugate, Dato-DXd. AstraZenecas rare-disease unit Alexion has completed a purchase and license agreement for early-stage rare-stage. gene therapy portfolio from Pfizer for a total consideration of $1 billion. AstraZeneca commits £100 million to advance uk energy efficiency. Energy from biomethane facility will supply sites in Macclesfield, Cambridge, Luton and Speke. Elmarie Bodes claims AstraZeneca refused to pay her more than $125,000 in bonuses because she worked from home last year. Bodes says she was owed a $124,000 performance bonus and $65,000 options.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, cancer, evaluate, advance, rise, AstraZenecas, Bodes, and the most common words in the summary are: astrazeneca, news, subscribe, see, cancer, drug, company, . One of the sentences in the summary was: Jefferies upgraded AstraZenecas stock from hold to buy after positive results from a late-stage study evaluating its antibody-drug conjugate, Dato-DXd. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #news #subscribe #see #cancer #drug #company.